Clinical characteristics and early outcomes in patients with COVID-19 treated with tocilizumab at a United States academic center
Authored by Casey A. Rimland, Camille E. Morgan, Griffin J. Bell, Min K. Kim, Tanner Hedrick, Ashley Marx, Brian Bramson, Heidi Swygard, Sonia Napravnik, John L. Schmitz, Shannon S. Carson, William A. Fischer, Joseph J. Eron, Cynthia L. Gay, and Jonathan B. Parr
Posted
Server
medRxiv
DOI
10.1101/2020.05.13.20100404
We describe early outcomes in 11 COVID-19 patients treated with the IL-6 receptor inhibitor tocilizumab. While C-reactive protein decreased, neither clinical improvement nor reduced temperature or oxygen requirements was observed in most patients. Our findings contrast with prior reports and raise questions about tocilizumab use in severe COVID-19.
You can write a PREreview of Clinical characteristics and early outcomes in patients with COVID-19 treated with tocilizumab at a United States academic center. A PREreview is a review of a preprint and can vary from a few sentences to a lengthy report, similar to a journal-organized peer-review report.
Before you start
We will ask you to log in with your ORCID iD. If you don’t have an iD, you can create one.
What is an ORCID iD?
An ORCID iD is a unique identifier that distinguishes you from everyone with the same or similar name.
